Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT01392092CompletedPrimary

Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers (NAC)

NCT00698737Completed

Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)

NCT00429767Completed

Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals

NCT00946660CompletedPrimary

Non-Treatment Study of Factors Affecting Cocaine Drug Choice

Showing all 4 trials

Research Network

Active Sponsors

  • Wayne State University4
  • National Institute on Drug Abuse (NIDA)3

Top Investigators

Related Conditions

  • Opioidrelated Disorders2
  • Cocaine Related Disorders2
  • Heroin Dependence2

Activity Timeline